骨肉瘤基因治疗的现状分析

doi:10.3760/cma.j.issn.1673-422X.2015.01.020

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (1): 74-76.doi: 10.3760/cma.j.issn.1673-422X.2015.01.020

骨肉瘤基因治疗的现状分析

张宁, 尤建宇, 国维纳, 赵宝林

130021长春，吉林大学中日联谊医院骨外科(张宁、尤建宇、赵宝林)；吉林大学第二医院重症监护室（国维纳）

收稿日期:2014-06-18 修回日期:2014-08-05 出版日期:2015-01-08 发布日期:2015-01-07
通讯作者: 赵宝林 E-mail:zhaobl@163.com

Status analysis of gene therapy in osteosarcoma

Zhang Ning, You Jianyu, Guo Weina, Zhao Baolin

Department of Orthopedics, China-Japan Union Hospital, Jilin University, Changchun 130021, China

Received:2014-06-18 Revised:2014-08-05 Online:2015-01-08 Published:2015-01-07
Contact: Zhao Baolin E-mail:zhaobl@163.com

摘要/Abstract

摘要： 目前，医学界普遍承认治疗骨肉瘤的最佳方法是基因治疗，常用的有抑癌基因治疗、反义基因治疗、自杀基因治疗、免疫基因治疗、联合基因治疗等。但是无论哪种基因治疗方法，都必须具备安全的基因载体。骨肉瘤的基因治疗方法近几年有所突破，在广泛应用的基础上，还应进一步强调基因载体的重要性。

关键词: 骨肉瘤, 基因疗法, 遗传载体

Abstract: At present, the medical profession generally acknowledged the best way to treat osteosarcoma is gene therapy, which includes tumor suppressor gene therapy, antisense gene therapy, suicide gene therapy, immune gene therapy, combined gene therapy, etc. But no matter what kind of gene therapy is that the gene must have a safe carrier. Gene therapy has made a breakthrough in osteosarcoma recently. On the basis of widespread use, we should emphasize the importance of gene vectors.

Key words: Osteosarcoma, Gene therapy, Genetic vectors

张宁, 尤建宇, 国维纳, 赵宝林. 骨肉瘤基因治疗的现状分析[J]. 国际肿瘤学杂志, 2015, 42(1): 74-76.

Zhang Ning, You Jianyu, Guo Weina, Zhao Baolin. Status analysis of gene therapy in osteosarcoma[J]. Journal of International Oncology, 2015, 42(1): 74-76.

参考文献

［1］ Rainusso N, Brawley VS, Ghazi A, et al. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumorinitiating cells in osteosarcoma［J］. Cancer Gene Ther, 2012, 19(3): 212-217. ［2］ Daft PG, Yuan K, Warram JM, et al. AlphaCaMKII plays a critical role in determining the aggressive behavior of human osteosarcoma［J］. Mol Cancer Res, 2013, 11(4): 349-359. ［3］ Baamonde A, CurtoReyes V, Juárez L, et al. Antihyperalgesic effects induced by the IL1 receptor antagonist anakinra and increased IL1 beta levels in inflamed and osteosarcomabearing mice［J］. Life Sci, 2011, 81(8): 673-682. ［4］ Liebau C, Roesel C, Schmidt S, et al. Immunotherapy by gene transfer with plasmids encoding IL12/IL18 is superior to IL23/IL18 gene transfer in a rat osteosarcoma model［J］. Anticancer Res, 2004, 24(5A): 2861-2867. ［5］ Strander H. Interferons and osteosarcoma［J］. Cytokine Growth Factor Rev, 2007, 18(56): 373380. ［6］ Fulda S, Debatin KM. 5Aza2′deoxycytidine and IFNgamma cooperate to sensitize for TRAILinduced apoptosis by upregulating caspase8［J］. Oncogene, 2006, 25(37): 5125-5133. ［7］ Gauthaman K, Fong CY, Arularasu S, et al. Human Wharton′s jelly stem cell conditioned medium and cellfree lysate inhibit human osteosarcoma and mammary carcinoma cell growth in vitro and in xenograft mice［J］. J Cell Biochem, 2013, 114(2): 366-377. ［8］ Wang YC, Zheng LH, Ma BA, et al. Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma［J］. Acta Histochem, 2011, 113(4): 402-408. ［9］ Tsang WP, Chau SP, Fung KP, et al. Modulation of multidrug resistanceassociated protein 1 (MRP1) by p53 mutant in Saos2 cells［J］. Cancer Chemother Pharmacol, 2003, 51(2): 161-166. ［10］ Xie XK, Yang DS, Ye ZM, et al. Construction of antisense cmyc recombinant adenovirus and its antitumor effects on osteosarcoma cell lines MG63 and U2OS［J］. Ai Zheng, 2005, 24(3): 292-297. ［11］ Martelli L, Di Mario F, Botti P, et al. Accumulation, platinumDNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wildtype status［J］. Biochem Pharmacol, 2007, 74(1): 20-27. ［12］ Ketola A, Mtt AM, Pasanen T, et al. Osteosarcoma and chondrosarcoma as targets for virus vectors and herpes simplex virus thymidine kinase/ganciclovir gene therapy［J］. Int J Mol Med, 2004, 13(5): 705-710. ［13］ Seto M, Yamazaki T, Sonoda J, et al. Suppression of tumor growth and pulmonary metastasis in murine osteosarcoma using gene therapy［J］. Oncol Rep, 2002, 9(2): 337-340. ［14］ Oosterhoff D, Witlox MA, van Beusechem VW, et al. Genedirected enzyme prodrug therapy for osteosarcoma: sensitization to CPT11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase2［J］. Mol Cancer Ther, 2003, 2(8): 765-771. ［15］ Lafleur EA, Jia SF, Worth LL, et al. Interleukin (IL)12 and IL12 gene transfer upregulate Fas expression in human osteosareoma and breast cancer cells［J］. Cancer Res, 2001, 61(10): 4066-4071. ［16］ Osaki M, Takeshita F, Sugimoto Y, et al. MicroRNA143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease13 expression［J］. Mol Ther, 2011, 19(6):1123-1130. ［17］ Nagamori M, Kawaguchi S, Murakami M, et al. In vivo immunogenicity of osteosarcoma cells that express B71a, an alternatively spliced form of B71［J］. Anticancer Res, 2009, 22(4): 2009-2013. ［18］ Posthumadeboer J, van Egmond PW, Helder MN, et al. Targeting JNKinteractingprotein1 (JIP1) sensitises osteosarcoma to doxorubicin［J］. Oncotarget, 2012, 3(10): 1169-1181. ［19］ Zhang ZY, Wang LQ, Fu CF, et al. Combination of targeting geneviro therapy with recombinant Fowlpox viruses with HN and VP3 genes on mouse osteosarcoma［J］. Eur Rev Med Pharmacol Sci, 2013, 17(6): 767-776. ［20］ Okumura K, Nakase M, Nakamura S, et al. Bax gene therapy for human osteosarcoma using cationic liposomes in vivo［J］. Once Rep, 2012, 17(4): 769-773.

[1]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[2]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛. 铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[3]	马小平, 常君丽, 孙星媛, 杨燕萍. 长非编码RNA调控骨肉瘤耐药机制的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 51-54.
[4]	周仁邦, 张仲传, 许志远, 朱勋兵. miR-219a-5p通过负调控HMGA2抑制骨肉瘤U2OS细胞增殖、侵袭和迁移[J]. 国际肿瘤学杂志, 2022, 49(4): 193-198.
[5]	李炳亮, 杨娅, 黄英丽, 司文, 李兴伟, 张元民, 卞继超, 陈语. miR-20a-5p靶向KDM6B对骨肉瘤细胞增殖、迁移和侵袭能力的影响[J]. 国际肿瘤学杂志, 2021, 48(2): 65-73.
[6]	杨晓1,李思2,彭锦3,王琳4,吴衣论4,冯颖2. 质膜型唾液酸酶NEU3活性对骨肉瘤MG-63细胞增殖与凋亡的影响[J]. 国际肿瘤学杂志, 2019, 46(4): 193-198.
[7]	贺启华. 微小RNA-24对骨肉瘤细胞U2OS体外增殖与迁移能力的影响及作用机制[J]. 国际肿瘤学杂志, 2017, 44(7): 490-495.
[8]	袁源, 李松霖, 王忠华, 沈会华, 李悟, 王卫东. 吴茱萸碱抑制Wnt/β-catenin信号通路诱导骨肉瘤MG-63细胞凋亡[J]. 国际肿瘤学杂志, 2017, 44(2): 86-90.
[9]	王伟,李召辉,郑晓霞,崔玉英. ErbB3在骨肉瘤细胞株Saos-2中的表达及其意义[J]. 国际肿瘤学杂志, 2016, 43(8): 593-596.
[10]	吴进, 陈志达, 曾文容, 林斌, 吴欣宇, 刘庆军. HERG基因调控NF-κB通道抑制骨肉瘤恶性表型的研究[J]. 国际肿瘤学杂志, 2016, 43(7): 508-514.
[11]	沈国琪，张春林. 受体酪氨酸激酶在骨肉瘤和尤文肉瘤中的作用[J]. 国际肿瘤学杂志, 2015, 42(7): 551-553.
[12]	任慧文,杨澄,苏宏伟,李宏伟. 微小RNA表达比在骨肉瘤中的预测作用[J]. 国际肿瘤学杂志, 2014, 41(8): 708-711.
[13]	杨澄, 苏宏伟, 任慧文, 李宏伟. 骨肿瘤的发生发展及转移[J]. 国际肿瘤学杂志, 2014, 41(7): 533-536.
[14]	牛鑫, 邓志华. 慢病毒载体及其在肿瘤基因治疗中的研究应用[J]. 国际肿瘤学杂志, 2014, 41(6): 422-424.
[15]	郭雨平, 汪得喜. 肺癌靶向基因的研究及价值[J]. 国际肿瘤学杂志, 2013, 40(7): 512-515.

骨肉瘤基因治疗的现状分析

Status analysis of gene therapy in osteosarcoma

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价